A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients

Infectious Diseases and Therapy

Volumn 4, Issue 1, 2015, Pages 67-78

  Patel, Nimish ^a   Nasiri, Mona ^a   Koroglu, Arden ^a   Bliss, Steven ^a   Davis, Melissa ^a   McNutt, Louise Anne ^b   Miller, Christopher ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c University Hospital   (United States)

Author keywords

Drug interactions; Epidemiology; Hepatitis C; Pharmacy

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL DEPRESSANT AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ADULT; ALCOHOLISM; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CROSS-SECTIONAL STUDY; DEMENTIA; DRUG EFFECT; DRUG INTERACTION; FEMALE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEPATITIS C; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; NEUROPATHY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SEIZURE;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84977105425     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-015-0058-x     Document Type: Article

References (18)

1. Olysio (simeprevir) tablet package insert. Titusville: Janssen Therapeutics, Division of Janssen Products, LP; 2013.
2. Sovaldi (sofosbuvir) package insert. Foster City: Gilead Sciences; 2013.
3. Recommendations for Testing, Managing, and Treating Hepatitis C. American Association for the Study of Liver Diseases/Infectious Diseases Society of America, with International Antiviral Society–USA. http://www.hcvguidelines.org/full-report-view. Accessed Sept 1, 2014.
4. Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447–53.
5. Centers for Disease Control & Prevention. Division of Viral Hepatitis. Surveillance for Viral Hepatitis—United States, 2011. http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/index.htm. Accessed Sept 1, 2014.
6. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006;7(8):549–57.
7. Marks M, Kulasegaram R. Drug-drug interactions and drug resistance will limit access to treatment in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2013;57(1):156–7.
8. Sulkowski MS. Hepatitis C virus-human immunodeficiency virus coinfection. Liver Int. 2012;32(Suppl 1):129–34.
9. Patel N, Veve M, Bliss S, Nasiri M, McNutt LA, Lazariu V, et al. Prevalence and predictors of important telaprevir drug interactions among patients coinfected with hepatitis C and human immunodeficiency virus. J Pharm Technol. 2014;30(5):159–67.
10. Patel N, Veve M, Nasiri M, Bliss S, McNutt LA, Lazariu V, et al. Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV. AIDS Patient Care STDS. 2014;28(10):513–6.
11. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS. 2012;31(26 Suppl 1):S39–53.
12. Up-to-Date, Inc. Lexi-interact online. Available from http://www.uptodate.com/crlsql/interact/frameset.jsp. Accessed Feb 1, 2014.
13. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593–4.
14. Seminerio MJ, Ratain MJ. Preventing adverse drug-drug interactions: a need for improved data and logistics. Mayo Clin Proc. 2013;88(2):126–8.
15. Patel N, Abdelsayed S, Veve M, Miller CD. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother. 2011;45(3):317–24.
16. Parikh ND, Levitsky J. Hepatotoxicity and drug interactions in liver transplant candidates and recipients. Clin Liver Dis. 2013;17(4):737–47 (x–xi).
17. Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transpl. 2012;18(7):989–1006.
18. Pai AB, Cardone KE, Manley HJ, St Peter WL, Shaffer R, Somers M, et al. Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach. Clin J Am Soc Nephrol. 2013;8(11):1988–99.